A drug interaction study between ticlopidine and cyclosporin in heart transplant recipients

European Journal of Clinical Pharmacology

Volumn 53, Issue 1, 1997, Pages 39-45

  Boissonnat, P ^b   De Lorgeril, M ^a   Perroux, V ^b   Salen, P ^a   Batt, A M ^c   Barthelemy, J C ^a   Brouard, R ^d   Serres, E ^d   Delaye, J ^b  

^a HÔPITAL NORD   (France)

^b LOUIS PRADEL HOSPITAL   (France)

^c Centre du Medicament URA CNRS 597   (France)

^d SANOFI   (France)

Author keywords

Cyclosporin; Cytochrome P450 3A4; Drug interaction; Heart transplantation; Ticlopidine

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYCLOSPORIN A; CYTOCHROME P450 ISOENZYME; TICLOPIDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BIOAVAILABILITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; FEVER; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; HEART TRANSPLANTATION; HUMANS; HYDROCORTISONE; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; TICLOPIDINE;

EID: 0030964028     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050334     Document Type: Article

References (27)

1. Kahan BD (1989) Cyclosporin. N Engl J Med 321: 1725-1729
2. Grattan MT, Moreno-Cabral CE, Starnes VA, Wilson B (1990) Eight-year results of cyclosporin-treated patients with cardiac transplants. J Thorac Cardiovasc Surg 99: 500-506
3. Yee GC (1991) Recent advances in cyclosporin pharmacokinetics. Pharmacotherapy 11: 130S-135S
4. Lake KD (1991) Management of drug interactions with cyclosporin. Pharmacotherapy 11: 110S-115S
5. Honcharik N, Yatscoff RW, Jeffery JR, Rish DN (1991) The effect of meal composition on cyclosporin absorption. Transplantation 52: 1087-1091
6. Savi P, Herbert JM (1996) ADP receptors on platelets and ADP-selective antiaggregating agents. Med Res Rev 16: 159-179
7. Batt AM, Siest G, Magdalou J, Galteau MM (1992) Enzyme induction by drugs and toxins. Clin Chim Acta 209: 109-112
8. Colli A, Buccino G, Cocciolo M, Rarravicini R, Elli GM, Scaltrini G (1987) Ticlopidine-theophylline interaction. Clin Pharmacol Ther 41: 358-362
9. Shah J, Teitelbaum P, Molony B, Gabuzda T, Massey I (1991) Single and multiple dose pharmacokinetics of ticlopidine in young and elderly patients. Br J Clin Pharmacol 32: 761-765
10. Uretsky BF, Muralli S, Reddy P, Rabbin P, Lee A, Griffith PB, Hardeshi RL, Trento A, Bahnson MT (1987) Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporin and prednisone. Circulation 76: 827-831
11. Grace AA, Barradas MA, Mikhailidis DP et al. (1987) Cyclosporin A enhances platelet aggregation. Kidney Int 32: 889-892
12. de Lorgeril M, Dureau G, Boissonnat P, et al. (1992) Platelet function and composition in heart transplant recipients compared with non-transplanted coronary patients. Arteriosclerosis Thrombosis 12: 222-228
13. de Lorgeril M, Boissonnat P, Mamelle N, et al. (1994) Platelet aggregation and HDL cholesterol are predictive of acute coronary events in heart transplant recipients. Circulation 89: 2590-2594
14. de Lorgeril M, Boissonnat P, Dureau G, Renaud S (1990) Low-dose aspirin and accelerated coronary artery disease in heart transplant recipients. J Heart Transplant 9: 449-450
15. de Lorgeril M, Dureau G, Boissonnat P, et al. (1991) Increased platelet aggregation after heart transplantation. Influence of aspirin. J Heart Lung Transplant 10: 600-603
16. Birmele B, Lebranchu Y, Bagros PH et al. (1991) Interaction of cyclosporin and ticlopidine. Nephrol Dial Transplant 6: 150-151
17. de Lorgeril M, Boissonnat P, Dureau G, Guidollet J, Renaud S (1993) Evaluation of ticlopidine, a novel inhibitor of platelet aggregation, in heart transplant recipients. Transplantation 55: 1195-1196
18. Ged C, Rouillon JM, Pichard L et al. (1989). The increase in urinary excretion of 6-beta-hydroxycortisol as a marker of human hepatic cytochromes P-450 3A induction. Br J Clin Pharmacol 28: 373-378
19. Reichtek N, Wilson J, St John Sutton M et al. (1982) Non invasive determination of left ventricular end systolic stress. Validation of the method and initial application. Circulation 65: 99-107
20. Desruennes M, Corcos MT, Cabrol A (1988) Doppler echocardiography for the diagnosis of acute cardiac allocraft rejection. J Am Coll Cardiol 12: 63-67
21. de Lorgeril M, Boissonnat P, Bizollon CA et al. (1992) Cyclosporin A pharmacokinetics in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction of lipid-lowering agent, fenofibrate. Eur J Clin Pharmacol 43: 161-165
22. Garraffo R, Lapalus P (1985) Simplified liquid chromatography analysis for cyclosporin A in blood and plasma with use of rapid extraction. J Chromatogr 337: 416-420
23. Zhiri A, Mayer HA, Michaux V, Wellman-Bednawska M, Siest G (1986) 6-beta-hydroxycortisol in serum and urine as determined by enzyme immunoassay on microtitre plates. Clin Chem 32: 2094-2097
24. Yoshimura R, Yoshimura N, Kusunose E et al. (1992) A comparative study of cyclosporine vs FK 506 : role of kidney microsomal cytochrome P450. Transplant Proc 24: 1395-1397
25. Boissonnat P, Salen P, Guidollet J et al. (1994) The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 58: 245-248
26. Massy ZA, Guijarro C, Kasiske BL (1995) Effect of fenofibrate in heart transplant patients. Transplantation 59: 451 (letter)
27. de Lorgeril M, Boissonnat P (1995) Effect of fenofibrate in heart transplant patients. Transplantation 59: 451